## Protocol Section
### Identification Module
**NCT ID:** NCT04188379

**Acronym:** ADVANCE

**Brief Title:** A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

**Official Title:** A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX 113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia

#### Organization Study ID Info
**ID:** ARGX-113-1801
#### Organization
**Class:** INDUSTRY
**Full Name:** argenx
#### Secondary ID Infos
**ID:** 2019-002100-41
**Type:** EUDRACT_NUMBER
### Status Module
#### Completion Date
**Date:** 2022-02-03

**Type:** ACTUAL

#### Disp First Post Date
**Date:** 2023-02-09

**Type:** ACTUAL

**Disp First Submit Date:** 2023-02-02
**Disp First Submit QC Date:** 2023-02-02

#### Expanded Access Info
#### Last Update Post Date
**Date:** 2024-03-07

**Type:** ACTUAL

**Last Update Submit Date:** 2024-03-04

**Overall Status:** COMPLETED

#### Primary Completion Date
**Date:** 2022-02-03

**Type:** ACTUAL

#### Start Date
**Date:** 2019-12-16

**Type:** ACTUAL

**Status Verified Date:** 2024-03

#### Study First Post Date
**Date:** 2019-12-05
**Type:** ACTUAL
**Study First Submit Date:** 2019-12-04
**Study First Submit QC Date:** 2019-12-04
### Sponsor Collaborators Module

#### Lead Sponsor

**Class:** INDUSTRY

**Name:** argenx

#### Responsible Party

**Type:** SPONSOR

### Oversight Module

**Is FDA Regulated Device:** False

**Is FDA Regulated Drug:** True

**Oversight Has DMC:** True

### Description Module

**Brief Summary:** This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in participants with primary ITP.

### Conditions Module

**Conditions:**

- Primary Immune Thrombocytopenia

**Keywords:**

- immune thrombocytopenia

- sustained platelet count response

- bleeding events

### Design Module

#### Design Info

**Allocation:** RANDOMIZED

**Intervention Model:** PARALLEL

##### Masking Info

**Masking:** QUADRUPLE

**Who Masked:**

- PARTICIPANT

- CARE_PROVIDER

- INVESTIGATOR

- OUTCOMES_ASSESSOR

**Primary Purpose:** TREATMENT

#### Enrollment Info

**Count:** 131

**Type:** ACTUAL

**Phases:**

- PHASE3

**Study Type:** INTERVENTIONAL

### Arms Interventions Module

#### Arm Group 1

**Description:** Patient receiving efgartigimod

**Intervention Names:**

- Biological: efgartigimod

**Label:** efgartigimod

**Type:** EXPERIMENTAL

#### Arm Group 2

**Description:** Patients receiving placebo

**Intervention Names:**

- Other: Placebo

**Label:** Placebo

**Type:** PLACEBO_COMPARATOR

### Interventions

#### Intervention 1

**Arm Group Labels:**

- efgartigimod

**Description:** Intravenous infusion of efgartigimod

**Name:** efgartigimod

**Other Names:**

- ARGX-113

**Type:** BIOLOGICAL

#### Intervention 2

**Arm Group Labels:**

- Placebo

**Description:** Intravenous infusion of placebo

**Name:** Placebo

**Type:** OTHER

### Outcomes Module

#### Primary Outcomes

**Description:** Proportion of subjects with chronic ITP with a sustained platelet count response was defined as achieving platelet counts of at least 50 × 10\^9 per litre for at least 4 of the 6 visits between weeks 19 and 24 of the study.

**Measure:** Proportion of patients with chronic ITP with a sustained platelet count response defined as achieving platelet counts of at least 50×10E9/L for at least 4 of the 6 visits between week 19 and 24 of the trial.

**Time Frame:** Up to five weeks (between visits 19 and 24)

#### Secondary Outcomes

**Description:** Extent of disease control, defined as the cumulative number of weeks over the planned 24-week treatment period with platelet counts of ≥50 × 10\^9/L in the chronic ITP population.

**Measure:** Extent of disease control defined as the number of cumulative weeks over the planned 24-week treatment period with platelet counts of ≥50×10E9/L in the chronic ITP population

**Time Frame:** Up to 24 weeks (treatment period)

**Description:** Proportion of subjects in the overall population achieving platelet counts of at least 50 × 10\^9/L for at least 6 of the 8 visits between weeks 17 and 24 of the study.

**Measure:** Proportion of patients in the overall population (chronic and persistent ITP) with a sustained platelet count response defined as achieving platelet counts of at least 50×10E9/L for at least 4 of the 6 visits between week 19 and 24 of the trial

**Time Frame:** Up to five weeks (between visits 19 and 24)

**Description:** Incidence of the World Health Organization (WHO)-classified bleeding events in the overall population.

Analysis was performed on Full Analysis Set population that included all randomized subjects. This secondary endpoint used the WHO-classified bleeding scale. Bleeding was the predominant clinical manifestation of ITP and was typically related to platelet count. Accordingly, measuring bleeding was important for monitoring this subject population. The WHO bleeding scale was neither specific to nor validated for ITP, but had been implemented in ITP clinical studies; no specific and validated tools for assessing bleeding in ITP were available.

**Measure:** Incidence and severity of the WHO-classified bleeding events

**Time Frame:** Up to 24 weeks (From Week 1 to Week 24)

**Description:** Proportion of subjects in the overall population (chronic and persistent ITP) with a sustained platelet count response, defined as achieving platelet counts of at least 50 × 10\^9/L for at least 4 of the 6 visits between weeks 19 and 24 of the study.

The analysis was performed on Full Analysis set population that included all randomized subjects in the study.

**Measure:** Proportion of patients in the overall population achieving platelet counts of at least 50 x 10^9/L for at least 6 of the 8 visits between week 17 and 24 of the trial.

**Time Frame:** Up to 7 weeks (between visits 17 and 24)

### Eligibility Module

**Eligibility Criteria:** Inclusion criteria:

* Ability to understand the requirements of the trial, to provide written informed consent (including consent for the use and disclosure of research-related health information), and to comply with the trial protocol procedures (including required trial visits).
* Male or female patient aged ≥18 years.
* Confirmed ITP diagnosis, at least 3 months before randomization and according to the American Society of Hematology Criteria, and no known other etiology for thrombocytopenia.
* Diagnosis supported by a response to a prior ITP therapy (other than thrombopoietin receptor agonists \[TPO-RAs\]), in the opinion of the investigator.
* Mean platelet count of \<30×10E9/L from 2 counts: 1 platelet count collected during the screening period and the predose platelet count on the day of randomization.
* At the start of the trial, the patient is either on concurrent ITP treatment(s) and has received at least 1 prior therapy for ITP in the past, or the patient is not on treatment for ITP but has received at least 2 prior treatments for ITP. Patients receiving permitted concurrent ITP treatment(s) at baseline, must have been stable in dose and frequency for at least 4 weeks prior to randomization.
* Women of childbearing potential must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at baseline before trial medication (infusion) can be administered.
* Women of childbearing potential should use a highly effective or acceptable method of contraception during the trial and for 90 days after the last administration of the IMP.

Exclusion criteria:

* ITP/thrombocytopenia associated with another condition, eg, lymphoma, chronic lymphocytic leukemia, viral infection, hepatitis, induced or alloimmune thrombocytopenia, or thrombocytopenia associated with myeloid dysplasia.
* Use of certain medications before the start of the studies (more details in the protocol)
* Patients who have a history of malignancy, including malignant thymoma, or myeloproliferative or lymphoproliferative disorders, unless deemed cured by adequate treatment with no evidence of recurrence for ≥3 years before screening. Patients with completely excised non-melanoma skin cancer (such as basal cell carcinoma or squamous cell carcinoma) or cervical carcinoma in situ would be permitted at any time.
* Uncontrolled hypertension, defined as a repeated elevated blood pressure exceeding 160 mmHg (systolic) and/or 100 mmHg (diastolic) despite appropriate treatments.
* History of any major thrombotic or embolic event within 12 months prior to randomization.
* History of coagulopathy or hereditary thrombocytopenia or a family history of thrombocytopenia.
* History of a recent or planned major surgery (that involves major organs eg, brain, heart, lung, liver, bladder, or gastrointestinal tract) within 4 weeks of randomization.
* Positive serum test at screening for an active viral infection with any of the following conditions: Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human immunodeficiency virus (HIV)
* Clinical evidence of significant unstable or uncontrolled acute or chronic diseases other than ITPdespite appropriate treatments which could put the patient at undue risk.
* Patients with known medical history of hypersensitivity to any of the ingredients of the IMP.
* Patients who previously participated in a clinical trial with efgartigimod and have received at least 1 administration of the IMP.
* Pregnant or lactating females. More details in the protocol

**Minimum Age:** 18 Years

**Sex:** ALL

**Standard Ages:**

- ADULT

- OLDER_ADULT

### Contacts Locations Module

#### Locations

**Location 1:**

**City:** Tucson

**Country:** United States

**Facility:** Investigator Site 0010038

**State:** Arizona

**Zip:** 85711

**Location 2:**

**City:** Washington

**Country:** United States

**Facility:** Investigator Site 0010045

**State:** District of Columbia

**Zip:** 20007

**Location 3:**

**City:** Jacksonville

**Country:** United States

**Facility:** Investigator Site 0010034

**State:** Florida

**Zip:** 32204

**Location 4:**

**City:** Ocala

**Country:** United States

**Facility:** Investigator site 0010037

**State:** Florida

**Zip:** 34474

**Location 5:**

**City:** Iowa City

**Country:** United States

**Facility:** Investigator Site 0010042

**State:** Iowa

**Zip:** 52242

**Location 6:**

**City:** Greenville

**Country:** United States

**Facility:** Investigator Site 0010046

**State:** North Carolina

**Zip:** 27834

**Location 7:**

**City:** Cleveland

**Country:** United States

**Facility:** Investigator Site 0010049

**State:** Ohio

**Zip:** 44106

**Location 8:**

**City:** Columbus

**Country:** United States

**Facility:** Investigator Site 0010040

**State:** Ohio

**Zip:** 44106

**Location 9:**

**City:** Philadelphia

**Country:** United States

**Facility:** Investigator Site 0010041

**State:** Pennsylvania

**Zip:** 19104

**Location 10:**

**City:** Linz

**Country:** Austria

**Facility:** Investigator Site 0430004

**Location 11:**

**City:** Vienna

**Country:** Austria

**Facility:** Investigator Site 0430002

**Location 12:**

**City:** Vienna

**Country:** Austria

**Facility:** Investigator Site 0430003

**Location 13:**

**City:** Brasschaat

**Country:** Belgium

**Facility:** Investigator Site 0320012

**Location 14:**

**City:** Brugge

**Country:** Belgium

**Facility:** Investigator Site 0320011

**Location 15:**

**City:** Leuven

**Country:** Belgium

**Facility:** Investigator Site 0320015

**Location 16:**

**City:** Turnhout

**Country:** Belgium

**Facility:** Investigator Site 0320014

**Location 17:**

**City:** Verviers

**Country:** Belgium

**Facility:** Investigator Site 0320020

**Location 18:**

**City:** Yvoir

**Country:** Belgium

**Facility:** Investigator site 0320002

**Location 19:**

**City:** Pleven

**Country:** Bulgaria

**Facility:** Investigator Site 3590001

**Location 20:**

**City:** Sofia

**Country:** Bulgaria

**Facility:** Investigator Site 3590002

**Location 21:**

**City:** Brno

**Country:** Czechia

**Facility:** Investigator Site 4200001

**Location 22:**

**City:** Olomouc

**Country:** Czechia

**Facility:** Investigator Site 4200008

**Location 23:**

**City:** Ostrava

**Country:** Czechia

**Facility:** Investigator Site 4200006

**Location 24:**

**City:** Praha

**Country:** Czechia

**Facility:** Investigator Site 4200007

**Location 25:**

**City:** Clermont-Ferrand

**Country:** France

**Facility:** Investigator Site 0330019

**Location 26:**

**City:** Créteil

**Country:** France

**Facility:** Investigator Site 0330009

**Location 27:**

**City:** Le Mans

**Country:** France

**Facility:** Investigator Site 0330015

**Location 28:**

**City:** Montpellier

**Country:** France

**Facility:** Investigator Site 0330018

**Location 29:**

**City:** Pessac

**Country:** France

**Facility:** Investigator Site 0330008

**Location 30:**

**City:** Périgueux

**Country:** France

**Facility:** Investigator Site 0330016

**Location 31:**

**City:** Rouen

**Country:** France

**Facility:** Investigator Site 0330017

**Location 32:**

**City:** Tbilisi

**Country:** Georgia

**Facility:** Investigator Site 9950006

**Location 33:**

**City:** Tbilisi

**Country:** Georgia

**Facility:** Investigator Site 9950007

**Location 34:**

**City:** Tbilisi

**Country:** Georgia

**Facility:** Investigator Site 9950008

**Location 35:**

**City:** Tbilisi

**Country:** Georgia

**Facility:** Investigator Site 9950009

**Location 36:**

**City:** Tbilisi

**Country:** Georgia

**Facility:** Investigator Site 9950011

**Location 37:**

**City:** Tbilisi

**Country:** Georgia

**Facility:** Investigator Site 9950012

**Location 38:**

**City:** Düsseldorf

**Country:** Germany

**Facility:** Investigator Site 0490010

**Location 39:**

**City:** Essen

**Country:** Germany

**Facility:** Investigator Site 0490008

**Location 40:**

**City:** Gießen

**Country:** Germany

**Facility:** Investigator Site 0490012

**Location 41:**

**City:** Budapest

**Country:** Hungary

**Facility:** Investigator Site 0360004

**Location 42:**

**City:** Debrecen

**Country:** Hungary

**Facility:** Investigator Site 0360006

**Location 43:**

**City:** Győr

**Country:** Hungary

**Facility:** Investigator Site 0360015

**Location 44:**

**City:** Nyiregyhaza

**Country:** Hungary

**Facility:** Investigator site 0360010

**Location 45:**

**City:** Szombathely

**Country:** Hungary

**Facility:** Investigator Site 0360014

**Location 46:**

**City:** Campobasso

**Country:** Italy

**Facility:** Investigator Site 0390012

**Location 47:**

**City:** Milan

**Country:** Italy

**Facility:** Investigator Site 0390014

**Location 48:**

**City:** Monza

**Country:** Italy

**Facility:** Investigator Site 0390020

**Location 49:**

**City:** Novara

**Country:** Italy

**Facility:** Investigator Site 0390015

**Location 50:**

**City:** Ravenna

**Country:** Italy

**Facility:** Investigator Site 0390010

**Location 51:**

**City:** Reggio Calabria

**Country:** Italy

**Facility:** Investigator Site 0390011

**Location 52:**

**City:** Reggio Emilia

**Country:** Italy

**Facility:** Investigator Site 0390018

**Location 53:**

**City:** Rimini

**Country:** Italy

**Facility:** Investigator Site 0390019

**Location 54:**

**City:** Roma

**Country:** Italy

**Facility:** Investigator Site 0390021

**Location 55:**

**City:** Siena

**Country:** Italy

**Facility:** Investigator Site 0390009

**Location 56:**

**City:** Torino

**Country:** Italy

**Facility:** Investigator Site 0390017

**Location 57:**

**City:** Trieste

**Country:** Italy

**Facility:** Investigator Site 0390016

**Location 58:**

**City:** Bunkyō-Ku

**Country:** Japan

**Facility:** Investigator Site 0810024

**Location 59:**

**City:** Hirakata

**Country:** Japan

**Facility:** Investigator Site 0810015

**Location 60:**

**City:** Hiroshima

**Country:** Japan

**Facility:** Investigator Site 0810010

**Location 61:**

**City:** Iruma

**Country:** Japan

**Facility:** Investigator site 0810017

**Location 62:**

**City:** Isehara

**Country:** Japan

**Facility:** Investigator site 0810011

**Location 63:**

**City:** Kashiwa

**Country:** Japan

**Facility:** Investigator Site 0810022

**Location 64:**

**City:** Maebashi

**Country:** Japan

**Facility:** Investigator site 0810018

**Location 65:**

**City:** Minato-Ku

**Country:** Japan

**Facility:** Investigator site 0810020

**Location 66:**

**City:** Niigata

**Country:** Japan

**Facility:** Investigator Site 0810021

**Location 67:**

**City:** Sapporo

**Country:** Japan

**Facility:** Investigator site 0810014

**Location 68:**

**City:** Shibukawa

**Country:** Japan

**Facility:** Investigator site 0810016

**Location 69:**

**City:** Shimotsuke

**Country:** Japan

**Facility:** Investigator Site 0810023

**Location 70:**

**City:** Shinjuku-Ku

**Country:** Japan

**Facility:** Investigator Site 0810025

**Location 71:**

**City:** Den Haag

**Country:** Netherlands

**Facility:** Investigator site 0310006

**Location 72:**

**City:** Rotterdam

**Country:** Netherlands

**Facility:** Investigator Site 0310005

**Location 73:**

**City:** Rotterdam

**Country:** Netherlands

**Facility:** Investigator Site 0310007

**Location 74:**

**City:** Białystok

**Country:** Poland

**Facility:** Investigator Site 0480030

**Location 75:**

**City:** Brzozów

**Country:** Poland

**Facility:** Investigator Site 0480015

**Location 76:**

**City:** Bydgoszcz

**Country:** Poland

**Facility:** Investigator Site 0480010

**Location 77:**

**City:** Chorzów

**Country:** Poland

**Facility:** Investigator Site 0480013

**Location 78:**

**City:** Gdańsk

**Country:** Poland

**Facility:** Investigator Site 0480012

**Location 79:**

**City:** Katowice

**Country:** Poland

**Facility:** Investigator Site 0480008

**Location 80:**

**City:** Lodz

**Country:** Poland

**Facility:** Investigator Site 0480011

**Location 81:**

**City:** Lublin

**Country:** Poland

**Facility:** Investigator Site 0480014

**Location 82:**

**City:** Nowy Sącz

**Country:** Poland

**Facility:** Investigator site 0480026

**Location 83:**

**City:** Wrocław

**Country:** Poland

**Facility:** Investigator Site 0480016

**Location 84:**

**City:** Kaluga

**Country:** Russian Federation

**Facility:** Investigator site 0070006

**Location 85:**

**City:** Petrozavodsk

**Country:** Russian Federation

**Facility:** Investigator Site 0070007

**Location 86:**

**City:** Rostov-on-Don

**Country:** Russian Federation

**Facility:** Investigator Site 0070013

**Location 87:**

**City:** Syktyvkar

**Country:** Russian Federation

**Facility:** Investigator Site 0070015

**Location 88:**

**City:** Tula

**Country:** Russian Federation

**Facility:** Investigator Site 0070012

**Location 89:**

**City:** Ufa

**Country:** Russian Federation

**Facility:** Investigator site 0070010

**Location 90:**

**City:** Barcelona

**Country:** Spain

**Facility:** Investigator Site 0340006

**Location 91:**

**City:** Barcelona

**Country:** Spain

**Facility:** Investigator Site 0340007

**Location 92:**

**City:** Burgos

**Country:** Spain

**Facility:** Investigator Site 0340030

**Location 93:**

**City:** Madrid

**Country:** Spain

**Facility:** Investigator Site 0340009

**Location 94:**

**City:** Madrid

**Country:** Spain

**Facility:** Investigator Site 0340014

**Location 95:**

**City:** Madrid

**Country:** Spain

**Facility:** Investigator Site 0340015

**Location 96:**

**City:** Palma De Mallorca

**Country:** Spain

**Facility:** Investigator site 0340012

**Location 97:**

**City:** Sevilla

**Country:** Spain

**Facility:** Investigator Site 0340013

**Location 98:**

**City:** Valencia

**Country:** Spain

**Facility:** Investigator Site 0340004

**Location 99:**

**City:** Valencia

**Country:** Spain

**Facility:** Investigator Site 0340011

**Location 100:**

**City:** Adana

**Country:** Turkey

**Facility:** Investigator Site 0900002

**Location 101:**

**City:** Adapazarı

**Country:** Turkey

**Facility:** Investigator Site 0900007

**Location 102:**

**City:** Ankara

**Country:** Turkey

**Facility:** Investigator Site 0900003

**Location 103:**

**City:** Ankara

**Country:** Turkey

**Facility:** Investigator Site 0900006

**Location 104:**

**City:** Ankara

**Country:** Turkey

**Facility:** Investigator Site 0900008

**Location 105:**

**City:** Ankara

**Country:** Turkey

**Facility:** Investigator Site 0900015

**Location 106:**

**City:** Edirne

**Country:** Turkey

**Facility:** Investigator Site 0900016

**Location 107:**

**City:** Istanbul

**Country:** Turkey

**Facility:** Investigator Site 0900013

**Location 108:**

**City:** Izmir

**Country:** Turkey

**Facility:** Investigator Site 0900004

**Location 109:**

**City:** Kocaeli

**Country:** Turkey

**Facility:** Investigator Site 0900014

**Location 110:**

**City:** Malatya

**Country:** Turkey

**Facility:** Investigator Site 0900018

**Location 111:**

**City:** Manisa

**Country:** Turkey

**Facility:** Investigator Site 0900005

**Location 112:**

**City:** Mersin

**Country:** Turkey

**Facility:** Investigator Site 0900010

**Location 113:**

**City:** Samsun

**Country:** Turkey

**Facility:** Investigator Site 0900009

**Location 114:**

**City:** Tekirdağ

**Country:** Turkey

**Facility:** Investigator Site 0900017

**Location 115:**

**City:** Trabzon

**Country:** Turkey

**Facility:** Investigator Site 0900019

**Location 116:**

**City:** Kharkiv

**Country:** Ukraine

**Facility:** Investigator Site 3800022

**Location 117:**

**City:** Mykolayiv

**Country:** Ukraine

**Facility:** Investigator site 3800006

**Location 118:**

**City:** London

**Country:** United Kingdom

**Facility:** Investigator Site 0440008

**Location 119:**

**City:** Rhyl

**Country:** United Kingdom

**Facility:** Investigator Site 0440010

**Location 120:**

**City:** Southampton

**Country:** United Kingdom

**Facility:** Investigator Site 0440012

**Location 121:**

**City:** Truro

**Country:** United Kingdom

**Facility:** Investigator Site 0440014

### IPD Sharing Statement Module

**IPD Sharing:** NO

## Derived Section

### Condition Browse Module - Ancestors

- ID: D000001791

- Term: Blood Platelet Disorders

- ID: D000006402

- Term: Hematologic Diseases

- ID: D000095542

- Term: Cytopenia

- ID: D000011696

- Term: Purpura, Thrombocytopenic

- ID: D000011693

- Term: Purpura

- ID: D000001778

- Term: Blood Coagulation Disorders

- ID: D000057049

- Term: Thrombotic Microangiopathies

- ID: D000006474

- Term: Hemorrhagic Disorders

- ID: D000001327

- Term: Autoimmune Diseases

- ID: D000007154

- Term: Immune System Diseases

- ID: D000006470

- Term: Hemorrhage

- ID: D000010335

- Term: Pathologic Processes

- ID: D000012877

- Term: Skin Manifestations

### Condition Browse Module - Browse Branches

- Abbrev: BC23

- Name: Symptoms and General Pathology

- Abbrev: All

- Name: All Conditions

- Abbrev: BC15

- Name: Blood and Lymph Conditions

- Abbrev: BC20

- Name: Immune System Diseases

- Abbrev: BC14

- Name: Heart and Blood Diseases

- Abbrev: Rare

- Name: Rare Diseases

### Condition Browse Module - Browse Leaves

- ID: M9556

- Name: Hemorrhage

- Relevance: LOW

- As Found: Unknown

- ID: M16680

- Name: Thrombocytopenia

- Relevance: HIGH

- As Found: Thrombocytopenia

- ID: M18945

- Name: Purpura, Thrombocytopenic, Idiopathic

- Relevance: HIGH

- As Found: Immune Thrombocytopenia

- ID: M14547

- Name: Purpura

- Relevance: LOW

- As Found: Unknown

- ID: M14550

- Name: Purpura, Thrombocytopenic

- Relevance: LOW

- As Found: Unknown

- ID: M5072

- Name: Blood Platelet Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M9490

- Name: Hematologic Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M3170

- Name: Cytopenia

- Relevance: LOW

- As Found: Unknown

- ID: M21977

- Name: Hemostatic Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M5059

- Name: Blood Coagulation Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M28682

- Name: Thrombotic Microangiopathies

- Relevance: LOW

- As Found: Unknown

- ID: M9560

- Name: Hemorrhagic Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M4629

- Name: Autoimmune Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M10200

- Name: Immune System Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M15680

- Name: Skin Manifestations

- Relevance: LOW

- As Found: Unknown

- ID: T3021

- Name: Immune Thrombocytopenia

- Relevance: HIGH

- As Found: Immune Thrombocytopenia

- ID: T3007

- Name: Idiopathic Thrombocytopenic Purpura

- Relevance: HIGH

- As Found: Primary Immune Thrombocytopenia

### Condition Browse Module - Meshes

- ID: D000013921

- Term: Thrombocytopenia

- ID: D000016553

- Term: Purpura, Thrombocytopenic, Idiopathic

### Misc Info Module

- Version Holder: 2024-05-24
